Ivonescimab

依沃西单抗

Report date: 2026/05/21 20:00:22
First In Class

Base Information

Drug NameIvonescimab
Drug Alias NameEvoximab依达方AK-112SMT-112
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockersVascular endothelial growth factor A inhibitors
TargetsProgrammed cell death protein 1Vascular endothelial growth factor A
Therapy Area/IndicationsBrain metastasesGastroesophageal Junction NeoplasmsSolid tumours +[50] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2024/05/24
Country/TerritoryBelgiumCanadaUnited States +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZhongshan Akeso Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSummit TherapeuticsAkeso Pharmaceuticals IncKangfang Biotechnology (Cayman) Co Ltd +[21] 
Inactive CompaniesN/A
Active IndicationsBrain metastasesGastroesophageal Junction NeoplasmsSolid tumours +[50] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A